The cost-effectiveness of human papillomavirus screening for cervical cancer: A review of recent modelling studies

European Journal of Health Economics

Volumn 6, Issue 1, 2005, Pages 30-37

  Holmes, Jeremy ^a   Hemmett, Lindsay ^a   Garfield, Susan ^b  

^a PMSI Healthcare   (United Kingdom)

^b Digene Corporation   (United States)

Author keywords

Cost per quality adjusted life year; Cost effectiveness ratio; Human papillomavirus testing; Life years saved; Screening strategies

Indexed keywords

CANCER SCREENING; COMPARATIVE STUDY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HUMAN; MATHEMATICAL MODEL; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; UTERINE CERVIX CANCER; WART VIRUS;

AGE FACTORS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 17444426058     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0254-1     Document Type: Review

References (20)

1. Anonymous (2003) Clinical management guidelines for obstetrician- gynecologists. ACOG practice bulletin no. 45. Obstet Gynaecol 102:417-427
2. Saslow D et al. (2002) American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52:342-362
3. Association of Reproductive Health Professionals (2004) Advances in cervical cancer protection. Clin Proc, Sept 2003
4. Wright TC et al. (1998) Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynaecol 178:962-966
5. Mandelblatt JS et al. (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287:2372-2381
6. Cuzick J, Sasieni P (1997) Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme. In: Franco, Monsonego (eds) New developments in cervical cancer screening & prevention. Oxford: Blackwell
7. Goldie S, Kim J, Wright T (2004) Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynaecol 103:619-631
8. Cuzick J et al. (1999) Assessing effectiveness, costs and cost-effectiveness of cervical cancer screening and HPV testing. Health Technol Assess 3:95-109
9. Goldie S (2002) Health economics and cervical cancer prevention: a global perspective. Virus Res 89:301-309
10. Kim J, Wright T, Goldie S (2002) Cost-effectiveness and alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287:2382-2390
11. Maxwell GL et al. (2002) Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynaecol 100:740-748
12. Mittendorf T, Schulenburg JMG von der, Petry K, Iftner T (2003) Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ 4:209-215
13. Ballegooijen M van et al. (1997) Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 76:651-657
14. Linos A, Riza E (2000) Comparisons of cervical cancer screening programmes in the European Union. Eur J Cancer 36:2260-2265
15. Clavel C et al. (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 89:1616-1623
16. Salzmann P, Kerlikowske K, Phillips K (1997) Cost effectiveness of extending screening mammography guidelines to include women 40-49 years of age. Ann Intern Med 127:955-965
17. Sherlaw-Johnson C & Philips Z (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. BR J Cancer 91:84-91
18. Annual country-specific inflation rates taken from OECD: Wages, Costs, Unemployment & Inflation, E 073
19. Average annual exchange rates taken from http://www.oaanda.com
20. Guidance for Manufacturers & Sponsors, National Institute for Clinical Excellence, June 2001. http://www.nice.org.uk